MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
By Eva van Rooij, E. Olson. Nature reviews. Drug discovery, 2012
629 citations recorded by the source corpus.
In recent years, prominent roles for microRNAs (miRNAs) have been uncovered in several cardiovascular disorders. The ability to therapeutically manipulate miRNA expression and function through systemic or local delivery of miRNA inhibitors, referred to as antimiRs, has triggered enthusiasm for miRNAs as novel therapeutic targets. Here, we focus on the pharmacokinetic and pharmacodynamic properties of current antimiR designs and their relevance to cardiovascular indications, and evaluate the opportunities and obstacles associated with this new therapeutic modality.
Subfields: Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/98d08af33696e7fc450d4b5745c71b6854327192
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Molecular Biology
Citations in the corpus
- Development of microRNA therapeutics is coming of age (2014, background): “…intervention (van Rooij et al, 2007; Gottwein & Cullen, 2008; Ventura & Jacks, 2009; Najafi-Shoushtari et al, 2010; Rayner et al, 2010; Grueter et al, 2012; van Rooij, 2012; van Rooij & Olson, 2012; Rottiers & Näär, 2012; Salta & De Strooper, 2012; Stenvang et al, 2012; Thorsen et al, 2012).”